SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Gilead Science (GILD) Followers
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
961 87 0 GILD
Emcee:  SybilNicolas Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
836Musings on the dolutegravir results: siliconinvestor.comDewDiligence_on_SI-7/12/2012
835London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announcnigel bates-7/12/2012
834Review Challenges Tamiflu Efficacy By MICHAEL SMITH, MedPage Today Stnsaf11/18/2012
833B'Rons: Just What the Doctor Ordered By DIMITRA DEFOTIS | A leader in innmopgcw-6/25/2011
832Ranexa sales managers allegedly employed questionable motivational technique: ptuck-1/10/2011
831Gilead Sciences • GILD-Nasdaq Buy • Price 37.19 on Dec. 21 by Roth Capital Partnmopgcw-12/25/2010
830cs: Gilead Sciences (GILD) OUTPERFORM [V] Industry Weighting: OVERWEIGHT R. Mehrmopgcw-12/18/2010
829Gilead 3rd-quarter profit driven by HIV sales 6:48pm EDT * Q3 adjusted EPS $0.9tnsaf-10/19/2010
828Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suptnsaf-9/15/2010
827GILD has some problems in the clinic… Problems in HCV: siliconinvestor.com siliDewDiligence_on_SI-7/21/2010
826GILD does not stand to make any money on the Viread gel product. The most conseDewDiligence_on_SI-7/20/2010
825GILD earnings release tomorrow after the close, coupled with the news today thatWhitmore G.-7/20/2010
824The problem in a nutshell is that there aren’t that many HIV patients remaining DewDiligence_on_SI-4/21/2010
823<i> A Growth Stock at a Huge Discount</i> . Perhaps. But also dour gtom pope-4/21/2010
822Ockham: Gilead Sciences: A Growth Stock at a Huge Discount by Ockham Research Stmopgcw-4/21/2010
821Tidbits from GILD’s 1Q10 CC: siliconinvestor.com (HIV) siliconinvestor.com (HCDewDiligence_on_SI-4/20/2010
820Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada® andtnsaf-4/20/2010
819Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hetnsaf-4/20/2010
818Gilead starts late stage tests of 4-in-1- HIV drug On Monday April 12, 2010, 6:tnsaf-4/13/2010
817U.S. Food and Drug Administration Approves Cayston® (Aztreonam for Inhalatitnsaf-2/22/2010
816Market was not impressed due to safety concerns. Now it's not impressed duetuck-12/15/2009
815FDA: Gilead cystic fibrosis studies flawed Tuesday, December 8, 2009, 10:15am PStnsaf-12/9/2009
814FDA: Gilead cystic fibrosis studies flawed Tuesday, December 8, 2009, 10:15am PStnsaf-12/9/2009
813Is this a good long term hold? 7 straight sessions need a bounce.fifty2weekhi-10/29/2009
812It's now paying the price of being overbought.tom pope-7/22/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News